Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan

Journal of Clinical Virology

Volumn 52, Issue 1, 2011, Pages 11-16

  Chen, Szu Ming ^a,b,c   Kung, Chien Min ^a   Yang, Wen Jen ^a,d   Wang, Hai Lung ^a  

^a YUANPEI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taiwan EandQ Clinical Laboratory Center   (Taiwan)

^d Chihsin Physical Examination Institute   (Taiwan)

Author keywords

ALT; AST; HBV; Hepatitis B; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS E ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFANT; LIVER FUNCTION TEST; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; SEROPREVALENCE; SEX DIFFERENCE; TAIWAN; UNIVERSITY; VACCINATION;

ADOLESCENT; CARRIER STATE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; LIVER FUNCTION TESTS; MALE; MASS VACCINATION; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; TAIWAN; YOUNG ADULT;

EID: 79961128537     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.06.012     Document Type: Article

References (56)

1. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
2. Chen D.S., Sung J.L. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol 1978, 25:423-430.
3. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., Arevalo J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995, 274:1201-1208.
4. Chen H.L., Chang M.H., Ni Y.H., Hsu H.Y., Lee P.I., Lee C.Y., et al. Seroepidemiology of hepatitis B virus infection in children, ten years of mass vaccination in Taiwan. JAMA 1996, 276:906-908.
5. Chen H.L., Chang C.J., Kong M.S., Huang F.C., Lee H.C., Lin C.C., et al. Pediatric fulminate hepatic failure in endemic areas of hepatitis B infection, 15 years after universal hepatitis B vaccination. Hepatology 2004, 30:257-264.
6. Lee C.L., Hsieh K.S., Ko Y.C. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003, 12:57-59.
7. Chen D.S., Hsu N.H., Sung J.L., Hsu T.C., Hsu S.T., Kuo Y.T., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257:2597-2603.
8. Chen D.S. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010, 25:19-25. Review. PMI. D. 20136972.
9. Chuang C.H. Hepatitis B control program in Taiwan. Acta Paediatr Jpn 1989, 31:645-648.
10. Hunga H., Chen T.H.H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence. Vaccine 2009, 27:6770-6776.
11. Stevens C.E., Neurath R.A., Beasley R.P., Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979, 3:237-241.
12. Su F.H., Chen J.D., Cheng S.H., Lin C.H., Liu Y.H., Chu F.Y. Seroprevalence of Hepatitis-B infection amongst Taiwanese University students 18 years following the commencement of a national hepatitis-B vaccination program. J Med Virol 2007, 79:138-143.
13. Huang M.L., Liao W.L., Ho M.S. HBV serological markers of vaccinated children in remote areas of Taiwan: emphasis on factors contributing to vaccine failure. Vaccine 2007, 25:6326-6333.
14. Huang K.Y., Lin S.R. Nationwide vaccination: a success story in Taiwan. Vaccine 2000, 18(1):S35-S38. PMID 10683542.
15. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003, 69:471-474.
16. Chiou S.S., Obata H., Takasaki T., Fukushima Y., Motoike Y., Okuda H., et al. Hepatitis viruses in southern Taiwan-mass survey of 2985 inhabitants. Gastroenterologia Japonica 1984, 19:344-350.
17. Lu S.N., Chen C.H., Chen T.M., Lee P.L., Wang J.H., Tung H.D., et al. virus infection in adolescents in a rural township-15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 2006, 24:759-765.
18. Da Villa G., Picciottoc L., Elia S., Peluso F., Montanaro F., Maisto T., et al. vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field. Vaccine 1995, 13:1240-1243.
19. Ng K.P., Saw T.L., Baki A., Rozainah K., Pang K.W., Ramanathan M. Impact of the expanded program of immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 2005, 194(3):163-168.
20. Schoub B.D., Matai U., Singh B., Blackburn N.K., Levin J.B. Universal immunization of infants with low doses of a low-cost, plasma-derived hepatitis B vaccine in South Africa. Bull World Health Organ 2002, 80:277-281.
21. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28:730-736.
22. Chongsrisawat V., Yoocharoen P., Theamboonlers A., Tharmaphornpilas P., Warinsathien P., Sinlaparatsamee S., et al. seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006, 11(10):1496-1502.
23. Lu J.J.Y., Cheng C.C., Chou S.M., Hor C.B., Yang Y.C., Wang H.L., et al. immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine 2009, 27:6613-6618.
24. Chen D.S., Hsu H.M., Bennett C.L., Pajeau T.S., Blumberg B., Chang P.Y., et al. A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. Cancer Causes Control 1996, 7:305-311. doi:10. 1007/BF00052935.
25. Popper H., Shafritz D.A., Hoofnagle J.H. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 1987, 7(4):764-772.
26. Ni Y.H., Chen D.S. Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol (Paris) 2010, 58:296-300. Epub 2010 January 29. PMID: 20116181.
27. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355. 10.1093/jnci/djp288.
28. Lee C.L., Ko Y.C., Hepatitis B Vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997, 99:351-353.
29. Saikia N., Talukdar R., Mazumder S., Khanna S., Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 2007, 83:32-39. 10.1136/pgmj.2006.044826.
30. Sua F.H., Cheng S.H., Li C.Y., Chen J.D., Hsiao C.Y., Chien C.C., et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007, 25:8085-8090.
31. Lin D.B., Wang H.M., Lee Y.L., Ling U.P., Changlais S.P., Chen C.J. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998, 16:1683-1687.
32. Altunay H., Kosan E., Birinci I., Aksoy A., Kirali K., Saribas S., et al. Are isolated anti-HBc blood donors in high risk group? The detection of HBV DNA in isolated anti-HBc cases with nucleic acid amplification test (NAT) based on transcription-mediated amplification (TMA) and HBV discrimination. Transfus Apheresis Sci 2010, 43:265-268.
33. Wang Z., Zhang J., Yang H., Li X., Wen S., Guo Y., et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen-positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003, 71:360-366.
34. Zanetti A., Tanzi E., Manzillo G., Maio G., Sbreglia C., Caporaso N., et al. Hepatitis B variant in Europe. Lancet 1988, 2(8620):1132-1133.
35. Carman W., Zanetti A., Karayiannis P., Waters J., Manzillo G., Tanzi E., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336:325-329.
36. Shizuma T., Hasegawa K., Ishikawa K., Naritomi T., Iizuka A., Kanai N., et al. Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus. J Gastroenterol 2003, 38:244-253.
37. Jongerius J.M., Wester M., Cuypers H.T., van Oostendorp W.R., Lelie P.N., van der Poel C.L., et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998, 38:56-59.
38. Stibbe W., Gerlich W.H. Structural relationships between minor and major proteins of Hepatitis B surface antigen. J Virol 1983, 46:626-628.
39. Neurath A.R., Kent S.B.H., Strick N., Taylor P., Stevens C.E. Hepatitis B virus contains pre S gene-encoded domains. Nature 1985, 315:154-156.
40. Petit M.A., Dubanchet S., Capel F., Voet P., Dauguet C., Hauser P. HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-Hbs and anti-pre-S1(21-47). Virology 1991, 180:483-491.
41. Pontisso P., Petit M.A., Bankowski M.J., Peeples M.E. Human liver plasma membranes contain receptors for the Hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol 1989, 63:1981-1988.
42. Gerlich W.H., Lu X., Heermann K.H. Studies on the attachment and penetration of Hepatitis B virus. J Hepatol 1993, 17(3):S10-S14.
43. Neurath A.R., Seto B., Strich N. Antibodies to synthetic peptides from the pre-S1 region of the hepatitis B virus envelope are virus-neutralizing and protective. Vaccine 1989, 7:234-236.
44. Kuroki K., Floreani M., Mimms M., Ganem D. Epitope mapping of the pre-S1 domain of the hepatitis B virus large surface protein. Virology 1990, 176:620-624.
45. D'Mello F., Partidos C.D., Steward M.W., Howard C.R. Definition of the primary structure of hepatitis B virus (HBV) pre S hepatocyte binding domain using random peptide libraries. Virology 1997, 237:319-326.
46. Moerman B., Moons V., Sommer H., Schmitt Y., Stetter M. Evaluation of sensitivity for wild-type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004, 50:159-162.
47. Thoai D.L. Detection HBsAg mutants by immunoassays. J Med Virol 2007, 79:S37-S41.
48. Cabrerizo M., Bartolome J., De Sequera P., Caramelo C., Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997, 8:1443-1447.
49. Scully L.J., Sung H., Pennie R., Gill P. Detection of hepatitis B virus DNA in the serum of Canadian hepatitis B surface antigen negative, anti-HBc positive individuals, using the polymerase chain reaction. J Med Virol 1994, 44:293-297.
50. Osiowy C. Detection of HBsAg mutants. J Med Virol 2006, 78:S48-S51.
51. Yang F., Yin Y., Wang F., Zhang L., Wang Y., Sun S. An altered pattern of liver apolipoprotein A-I isoforms is implicated in male chronic hepatitis B progression. J Proteome Res 2010, 9:134-143.
52. Yuen M.F., Tanaka Y., Fong D.Y., Fung J., Wong D.K., Yuen J.C., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2008, 50:7-9.
53. Lee C.M., Lu S.N., Changchien C.S., Yeh C.T., Hsu T.T., Tang J.H., et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999, 86(7):1143-1150.
54. Rogers A.B., Theve E.J., Feng Y., Fry R.C., Taghizadeh K., Clapp K.M., et al. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 2007, 67(24):11536-11546.
55. Chitturi S., Farrell G.C., Hashimoto E., Saibara T., Lau G.K., Sollano J.D. Asia-Pacific working party on NAFLD Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007, 22(6):778-787.
56. Department of Health. Health and vital statistics, Republic of China 1997. The Executive Yuan 1998;2:7-10.